background-image
Abbreviations:

4-1BB, tumor necrosis factor receptor superfamily member 9; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor from the tumor necrosis factor family; BAK, Bcl-2 homologous antagonist killer; BAX, Bcl-2-associated X protein; BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BCR, B-cell receptor; BH, Bcl-2 homology domain; BiTE, Bispecific T-cell Engager; C5, complement component 5; CD, cluster of differentiation; CIT, chemotherapy-induced thrombocytopenia; CLDN18.2, Claudin-18 isoform 2; DARPin, designed ankyrin repeat proteins; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like protein 3; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; Fab, fragment antigen-binding; FAP, fibroblast activation protein; Fc, fragment crystallizable; FLT3, fms-like tyrosine kinase 3; GEJ, gastroesophageal junction; GM-CSF, granulocyte-macrophage colony-stimulating factor; GvHD, graft versus host disease; HCC, hepatocellular carcinoma; HLE, half-life extended; IL-2R, interleukin 2 receptor; IL-21R, interleukin 21 receptor; IL-2Rα, interleukin 2 receptor alpha; KRAS, Kirsten rat sarcoma; MAC, membrane attack complex; MCL-1, myeloid cell leukemia-1; mCRPC, metastatic castration-resistant prostate cancer; MetMel, metastatic melanoma; MM, multiple myeloma; MOA, mechanism of action; MUC17, mucin 17; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; PNH, paroxysmal nocturnal hemoglobinuria; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RAS, rat sarcoma; R/R, relapsed or refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1; TPO, thrombopoietin; TPO-R, thrombopoietin receptor; Treg, regulatory T cell.

Amgen Oncology
Pipeline

Select a button below to learn more

SOLID MALIGNANCIES

MALIGNANCIES

TARGETS

HEMATOLOGIC DISEASES

DISEASES

TARGETS

PIPELINE

BITE® PLATFORM

BIOSIMILARS

MODALITIES

SMALL MOLECULE

Small molecules remain a common treatment option, with a chemical compound as their active ingredients.1 Small molecules are usually administered orally but may also be injected or infused.2

Small-molecule drugs may provide the best or only current way to treat certain diseases.3 Because of their size, these compounds can pass through cell walls to engage targets inside the cell.1 They can also be designed to cross the blood-brain barrier and engage targets that may contribute to neurological illnesses.4

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; KIF18A, kinase-like protein 18A; KRAS, Kirsten rat sarcoma; MCL-1, myeloid cell leukemia-1; MM, multiple myeloma; NSCLC, non-small cell lung cancer.

References
1. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/small-molecule-drug. Accessed 7/29/21. 2. Amgen Science. https://www.amgenscience.com/items/small-molecules/. Accessed 7/29/21. 3. Gurevich EV, et al. Handb Exp Pharmacol. 2014;219:1-12. 4. Pardridge WM. J Cereb Blood Flow Metab. 2012;32:1959-1972. 5. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 7/27/21. 6. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02675452. Accessed 7/29/21. 7. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03465540. Accessed 7/29/21. 8. Govindan R, et al. Presented at: American Society of Clinical Oncology; Virtual Meeting; June 4–8, 2021. 9. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02303821. Accessed 7/29/21. 10. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04191616. Accessed 7/29/21. 11. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03859427. Accessed 7/29/21. 12. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03600883. Accessed 8/27/21. 13. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04185883. Accessed 8/27/21. 14. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04303780. Accessed 7/29/21.
Molecule
Modality5
Target5
Areas of Investigation6
AMG 176
Modality5
SMALL MOLECULE
Target5
Areas of Investigation6
Molecule
Modality5
Target5
Areas of Investigation7
AMG 397
Modality5
SMALL MOLECULE
Target5
Areas of Investigation7
Molecule
Modality5
Target8
Areas of Investigation5
AMG 650
Modality5
SMALL MOLECULE
Target8
Areas of Investigation5
Molecule
Modality5
Target5
Areas of Investigation9-11
Carfilzomib
Modality5
SMALL MOLECULE
Target5
Areas of Investigation9-11
Molecule
Modality5
Target5
Areas of Investigation12-14
Sotorasib
Modality5
SMALL MOLECULE
Target5
Areas of Investigation12-14

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; KIF18A, kinase-like protein 18A; KRAS, Kirsten rat sarcoma; MCL-1, myeloid cell leukemia-1; MM, multiple myeloma; NSCLC, non-small cell lung cancer.

References
1. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/small-molecule-drug. Accessed 7/29/21. 2. Amgen Science. https://www.amgenscience.com/items/small-molecules/. Accessed 7/29/21. 3. Gurevich EV, et al. Handb Exp Pharmacol. 2014;219:1-12. 4. Pardridge WM. J Cereb Blood Flow Metab. 2012;32:1959-1972. 5. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 7/27/21. 6. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02675452. Accessed 7/29/21. 7. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03465540. Accessed 7/29/21. 8. Govindan R, et al. Presented at: American Society of Clinical Oncology; Virtual Meeting; June 4–8, 2021. 9. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02303821. Accessed 7/29/21. 10. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04191616. Accessed 7/29/21. 11. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03859427. Accessed 7/29/21. 12. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT03600883. Accessed 8/27/21. 13. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04185883. Accessed 8/27/21. 14. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04303780. Accessed 7/29/21.

This website may not be accessible on your mobile device; if so, please view on your desktop or tablet.